Sebaceous Carcinoma Arising in Ovarian Teratoma

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jacinta Murray ◽  
Patrick McIlwaine ◽  
Patrick J. Morrison ◽  
W. Glenn McCluggage
2018 ◽  
Vol 2 (2) ◽  
pp. 136-141
Author(s):  
Leart Berdica ◽  
Teona Bushati ◽  
Alfred Aga ◽  
Erisa Kola ◽  
Rustem Celami ◽  
...  

2016 ◽  
Vol 78 (5) ◽  
pp. 512-515
Author(s):  
Masakazu OTSU ◽  
Kotaro NAGASE ◽  
Yumi KIMURA ◽  
Reiko SHIRAI ◽  
Shinichi KOBA ◽  
...  
Keyword(s):  

2010 ◽  
Vol 72 (1) ◽  
pp. 48-53
Author(s):  
Takashi SAKAI ◽  
Yoshitaka KAI ◽  
Seiichi SATO ◽  
Mizuki GOTO ◽  
Fumiaki SHIMIZU ◽  
...  

2011 ◽  
Vol 73 (2) ◽  
pp. 152-156
Author(s):  
Mio MACHIDA ◽  
Yasutoshi HIDA ◽  
Yoshiaki KUBO ◽  
Seiji ARASE ◽  
Shin-ichi ANSAI

2018 ◽  
Vol 64 (6) ◽  
pp. 708-715
Author(s):  
Natalya Severskaya ◽  
Andrey Rodichev ◽  
Aleksey Ilin ◽  
Dmitriy Semin ◽  
Pavel Isaev ◽  
...  

Struma ovarii is a rare variant of the mature ovarian teratoma composed of more than 50% thyroid tissue. Thyroid type carcinoma can occur in 5% of struma ovarii. Given the rarity of this pathology, as well as the different clinical course, approaches to the treatment of this disease are controversial. The proposed approaches to treatment vary from ovarian resection to total hysterectomy with bilateral salpingo-oophorectomy and adjuvant therapy. We present here 6 case reports of thyroid type carcinoma in struma ovarii and outcome of patients treated in our clinic. All patients had pelvic surgery of different extent, followed by thyroidectomy and radioiodine therapy. The incidence of metastasis is 67% (4/6), 2 - intraperitoneal metas-tases, 2 - bone metastases. Among patients with metastases, 2 have reached a complete response, one with a good response continues treatment, one had progression. The follow-up period is 1 to 15 years (median 4 years). One patient with follicular carcinoma died of progression 8 years after diagnosis. The remaining patients are alive.


2020 ◽  
Author(s):  
K Ben Hamida ◽  
M Bouhani ◽  
S Sghaier ◽  
S Essghaier ◽  
L Charfi ◽  
...  
Keyword(s):  

2021 ◽  
Author(s):  
Anahita Emamian ◽  
Daniella Santi ◽  
Marveen Appu ◽  
Wendy Tcheng ◽  
Karen S. Fernandez
Keyword(s):  

2021 ◽  
pp. 17-23
Author(s):  
Koji Obara ◽  
Tomoko Ono ◽  
Itaru Toyoshima

In anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, progressive cerebellar atrophy potentially leads to severe sequelae. We encountered a patient with anti-NMDAR antibody encephalitis who showed a decrease of blood flow in the cerebellum. A 15-year-old girl presented with consciousness disturbance. Influenza encephalopathy was suspected, and she was treated with glucocorticoid pulse therapy, high-dose intravenous immunoglobulins, and plasma exchange sequentially. She subsequently underwent left oophorectomy due to the presence of anti-NMDAR antibodies and a left ovarian teratoma. In spite of the surgery, her neuropsychiatric symptoms persisted, and she recovered slowly after the introduction of oral methotrexate (MTX). Sequential cerebral blood flow monitoring with single-photon emission computed tomography showed marked cerebellar hypoperfusion. Although mild impairments including working memory and verbal fluency persisted, she eventually returned to high school 3 years after onset. Profound cerebellar hypoperfusion including lobules VI and VII may be the reason for her working memory impairment and speaking problems. Oral MTX may be a promising alternative treatment for some refractory cases of anti-NMDAR encephalitis.


Sign in / Sign up

Export Citation Format

Share Document